Ombitasvir
CAS: 1258226-87-7
Ref. 3D-AO178040
1g | 722,00 € | ||
2g | 1.019,00 € | ||
100mg | 272,00 € | ||
250mg | 426,00 € | ||
500mg | 568,00 € |
Información del producto
- 2,2′-[[(2S,5S)-1-[4-(1,1-Dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-<span class="text-smallcaps">L</smallcap>-valyl-<smallcap>L</span>-prolinamide]
- <span class="text-smallcaps">L</smallcap>-Prolinamide, 2,2′-[[(2S,5S)-1-[4-(1,1-dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-<smallcap>L</span>-valyl-
- L-Prolinamide, 2,2′-[[(2S,5S)-1-[4-(1,1-dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-L-valyl-
- ABT 267
- 2,2′-[[(2S,5S)-1-[4-(1,1-Dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-L-valyl-L-prolinamide]
Ombitasvir is a potent inducer of the cytochrome P450 enzyme system. It has been shown to inhibit the growth of infectious diseases by binding to α7 nicotinic acetylcholine receptors, which are located on cells in the liver, brain, and other organs. Ombitasvir has also been shown to be a potent inhibitor of antiviral resistance by binding to the viral envelope protein. This drug is used as an oral treatment for chronic hepatitis C infections with or without HIV co-infection in adults. It is also used in combination with other antiviral drugs for the treatment of chronic HBV infection in adults.
Propiedades químicas
Consulta técnica sobre: 3D-AO178040 Ombitasvir
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.